摘要
目的探讨聚乙二醇干扰素α-2a联合胸腺肽-α1对慢性乙型肝炎(chronic hepatitis B,CHB)的疗效。方法收集CHB患者140例,根据随机数字表法分为联合组和对照组,各70例。对照组采用聚乙二醇干扰素α-2a治疗,联合组采用聚乙二醇干扰素α-2a联合胸腺肽-α1治疗。比较两组患者治疗前、治疗12周、24周、48周时的病毒载量、病毒应答及生存质量评分情况。结果联合组在治疗12周、24周、48周时HBV DNA载量水平明显低于对照组,病毒学应答率高于对照组(P<0.05)。在治疗24周时,联合组乏力、焦虑评分及治疗48周时全身症状、腹部症状、乏力、活动、焦虑评分均明显高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论胸腺肽-α1具有抗病毒和调节免疫功能的作用,聚乙二醇干扰素α-2a联合胸腺肽-α1治疗CHB有较多优势,可作为CHB治疗的一个有效方法进行推广。
Objective To investigate the efficacy of pegylated interferon α-2a with thymosin-α1 in treatment of chro- nic hepatitis B （CHB）. Methods One hundred and forty CHB patients were collected and randomly divided into com- bination group （70 cases） and control group （70 cases） according to random number table. Control group were treated with only pegylated interferon α-2a, combination group were treated with pegylated interferon α-2a and thymosin-α1. The viral load, viral response and quality of life score situation before treatment, at 12 weeks, 24 weeks, 48 weeks were compared between two groups. Results The levels of HBV DNA load in combination group at 12 weeks, 24 weeks, 48 weeks after treatment were significantly lower than those in control group （P 〈 0.05） ; and virological response rate in combination group at 12 weeks, 24 weeks, 48 weeks after treatment were significantly higher than those in control group （P 〈 0.05）. The fatigue, anxiety scores at 24 weeks after treatment, and the systemic, abdominal symptoms, fatigue, activity, anxiety scores at 48 weeks after treatment in combination group were significantly higher than those in control group （P 〈 0.05）. The incidence of adverse reaction between two groups was not significantly different （P 〉 0.05 ）. Conclusion Thymosin-α1 has anti-virus and immue regulating function, pegylated interferon α-2a combined with thy- mosin-α1 in treating CHB has many advantages, therefore it can be promoted as an effective method for the treatment of CHB.
出处
《胃肠病学和肝病学杂志》
CAS
2015年第8期966-968,972,共4页
Chinese Journal of Gastroenterology and Hepatology
